NSCALE/KONTENA
22.7.2024 03:45:01 CEST | Business Wire | Press release
Nscale, a fully vertically integrated AI cloud platform, today announced the acquisition of Kontena, a leader in high-density modular data centres and AI Data Centre solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721172829/en/
Joshua Payne, Founder and CEO, Nscale (Photo: Business Wire)
This acquisition marks a significant step forward in Nscale's mission to provide the infrastructure backbone to the growing generative AI market through cost-effective, high-performance solutions that unlock AI's full potential.
Jef Laurijssen, CEO of Kontena, commented: “Joining forces with Nscale provides us with an incredible opportunity to accelerate the development and deployment of cutting-edge Generative AI Data Centre solutions. Our combined expertise will enable us to deliver unparalleled value to our customers in the AI and HPC markets.”
Capitalising on Kontena’s innovative KONNECT ecosystem combined with Nscale’s extensive infrastructure capabilities, the two companies will deliver high-performance solutions. Kontena's flagship product, the EDGE data room, is a fully modular Generative AI Data Centre solution designed to meet the complex demands of advancing AI development. The EDGE data room is one of the world’s first modular solution deploying AI infrastructure on-premises and in remote locations, far quicker and at lower cost than traditional Tier 3 Data Centres.
Nscale’s acquisition of Kontena bolsters its commitment to sustainability. Kontena’s modular AI data centre solutions will enable Nscale to deliver faster and more cost-effective deployments for customers at its 100% renewable data centre sites in Norway and the US.
Joshua Payne, CEO of Nscale, commented: “The acquisition of Kontena allows Nscale to design, build, and deploy bespoke GPU clusters at scale for global Generative AI customers more quickly and more cost-effectively than the competition. Building Kontena into the Nscale value chain will allow us to deliver bespoke GPU superclusters and data centre builds for our large supercluster and hyperscale customers across Nscale’s 500MW of greenfield data centre capacity. This modular system can be deployed in Nscale’s data centres, on-premise, or at the edge to deliver unrivalled speed, performance, and efficiency on GenAI workloads. This is an important step towards our goal of vertical integration.”
This acquisition underscores Nscale’s dedication to driving innovation and delivering exceptional value to its customers. It follows Nscale’s recent announcement of a strategic partnership with Open Innovation AI, a leading GPU orchestration platform in MENA, targeting the deployment of 30,000 GPUs over the next 3 years, further solidifying its commitment to AI infrastructure and optimised workloads for global markets.
About Nscale
Nscale is a fully vertically integrated AI GPU Cloud provider delivering compute to the generative AI market at scale. Leveraging its 60MW renewable energy-powered data centre in Norway and a pipeline of over 500MW of greenfield data centres in the US. Nscale enables customers to run efficient and scalable AI training, fine-tuning, and compute-intensive workloads, supporting advanced AI research and development. Nscale provides the AI infrastructure backbone to the generative AI market.
About Kontena
Founded in 2018, Kontena specialises in high-density data centres and HPC solutions, combining innovation with practicality. The company recently collaborated with ElioVP and Bluesio to develop better and more innovative AI and HPC solutions.
For more information about Nscale’s AI & HPC solutions and the Kontena acquisition, visit nscale.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240721172829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
